Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(23 sites)

China

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

China-Japan Friendship Hospital, Beijing

Peking University Third Hospital, Beijing

West China Hospital, Sichuan University, Chengdu

The First Affiliate Hospital of Dalian Medical University, Dalian

Fujian Medical University Union Hospital, Fuzhou

Fujian Provincial Cancer Hospital, Fuzhou

Cancer Center of Guangzhou Medical University, Guangzhou

Sun Yai-Sen Memorial Hospital, Sun Yai-Sen University, Guangzhou

Zhejiang Cancer Hospital, Hangzhou

The Affiliated Tumor Hospital of Harbin Medical University, Harbin

The First Hospital of Lanzhou University, Lanzhou

Linyi Cancer Hospital, Linyi

Nantong Tumor Hospital, Nantong

Shanghai Jiao Tong University School Medicine, Shanghai

Fudan University Shanghai Cancer Center, Shanghai

Second People's Hospital of Shenzhen, Shenzhen

The Forth Hospital of Hebei Medical University, Shijiazhuang

First Hospital of Shanxi Medical University, Taiyuan

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

Henan Cancer Hospital, Zhengzhou

The First Affiliated Hospital of Zhengzhou University, Zhengzhou